Now showing items 1-4 of 4

    • Ajani, Jaffer A.; Moiseyenko, Vladimir M.; Tjulandin, Sergei; Majlis, Alejandro; Constenla, Manuel; Boni, Corrado; Rodrigues, Adriano; Fodor, Miguel; Chao, Yee; Voznyi, Edouard; Marabotti, Cindy; Van Cutsem, Eric (2007)
      Purpose For patients with advanced gastric or gastroesophageal cancer (AGGEC) providing clinical benefit with improved palliation is highly desirable. However, a prospective evaluation of clinical benefit in AGGEC patients ...
    • Ajani, Jaffer A.; Fodor, Miguel; Tjulandin, Sergei; Moiseyenko, Vladimir M.; Chao, Yee; Cabral, Sebastiao; Majlis, Alejandro; Assadourian, Sylvie; Van Cutsem, Eric (JOURNAL OF CLINICAL ONCOLOGY, 2005-08-20)
      Purpose The purpose of this study was to define the contribution of docetaxel to combination chemotherapy in the outcome of patients with advanced gastric or gastroesophageal adenocarcinoma. We compared the overall response ...
    • Van Cutsem, Eric; Moiseyenko, Vladimir M.; Tjulandin, Sergei; Majlis, Alejandro; Constenla, Manuel; Boni, Corrado; Rodrigues, Adriano; Fodor, Miguel; Chao, Yee; Voznyi, Edouard; Risse, Marie-Laure; Ajani, Jaffer A. (AMER SOC CLINICAL ONCOLOGY, 2006-11-01)
      Purpose In the randomized, multinational phase II/III trial (V325) of untreated advanced gastric cancer patients, the phase II part selected docetaxel, cisplatin, and fluorouracil (DCF) over docetaxel and cisplatin for ...
    • Ajani, Jaffer A.; Moiseyenko, Vladimir M.; Tjulandin, Sergei; Majlis, Alejandro; Constenla, Manuel; Boni, Corrado; Rodrigues, Adriano; Fodor, Miguel; Chao, Yee; Voznyi, Edouard; Awad, Lucile; Van Cutsem, Eric (2007)
      Purpose Therapy of patients with advanced gastric or gastroesophageal junction cancer should provide symptom relief and improve quality of life ( QOL) because most patients are symptomatic at baseline. Using validated ...